Chronic hepatitis B: Treatment alert

Liver International

Volumn 26, Issue SUPPL. 2, 2006, Pages 47-58

  Chang, Ting Tsung ^a   Zhuang, Hua ^b   Jia, Jidong ^c   Leung, Nancy Wai Yee ^d   Guan, Richard ^e   Jafri, S M Wasim ^f   Lesmana, Laurentius A ^g   Liaw, Yun Fan ^h   Locarnini, Stephen ⁱ   Omata, Masao ^j   Sollano, Jose D ^k   Suh, Dong Jin ^l   Mahachai, Varocha ^m   Phiet, Pham Hoang ⁿ   Sarin, Shiv K ^o   Yao, Guangbi ^p   Yoon, Seung Kew ^q  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^e NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^f AGA KHAN UNIVERSITY   (Pakistan)

^g UNIVERSITY OF INDONESIA   (Indonesia)

^h CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

ⁱ VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^j UNIVERSITY OF TOKYO   (Japan)

^k UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

^l Asan Medical Center   (South Korea)

^m CHULALONGKORN UNIVERSITY   (Thailand)

ⁿ UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

^o UNIVERSITY OF DELHI   (India)

^p Shanghai Jing An Qu Central Hospital   (China)

^q The Catholic University of Korea   (South Korea)

more..

Author keywords

ALT levels; Consensus statement; HBeAgnegative; HBeAgpositive; HBVDNA levels; Treatment guidelines

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PLACEBO; TELBIVUDINE; THYMOSIN ALPHA1; VIRUS DNA;

ANTIBIOTIC RESISTANCE; ASIA; CHILD CARE; COMORBIDITY; CONSENSUS DEVELOPMENT; CONTINUING EDUCATION; DRUG COST; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; PACIFIC ISLANDS; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICIAN; PREGNANCY; REVIEW; RISK ASSESSMENT; SEROCONVERSION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 33750701423     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01374.x     Document Type: Review

References (56)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatol 2004; 11: 97-107.
2. Mohamed R, Desmond P, Suh D J, et al. Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol 2004; 19: 958-69.
3. de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002, Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39 (Suppl. 1): S3-25.
4. Liaw Y F, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005; 25: 472-89.
5. Lok A S, McMahon B J. Chronic hepatitis B: Update of recommendations. Hepatology 2004; 39: 857-61.
6. Keeffe E B, Dieterich D T, Han S H, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 87-106.
7. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-24.
8. Keeffe E B, Dieterich D T, Han S H B, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 2006; 4: 936-62.
9. Centers for Disease Control and Prevention (CDC)-Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. October 6, 2005. Last update: 2006. Hvailable at: http://AIDSinfo.nih.gov. Accessed March 28, 2006.
10. Papatheodoridis G V, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-9.
11. Sokal E M, Kelly D A, Mizerski J, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006; 43: 225-32.
12. Hadziyannis S J, Tassopoulos N C, Heathcote E J, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-81.
13. Chang T T, Gish R G, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
14. Lai C L, Shouval D, Lok A S, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
15. Janssen H L, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005; 365: 123-9.
16. Lau G K, Piratvisuth T, Luo K X, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
17. Lai C L, Gane E, Liaw Y F, et al. Telbivudine (LDT) vs. lamivudine for chronic hepatitis B: First-year results from the International Phase III Globe Trial (abstract LB1). Hepatology 2005; 42: 748A.
18. Lim S G, Ng T M, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006; 166: 49-56.
19. Lim S G, Wai C T, Lee Y M, et al. A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther 2006; 11: 245-53.
20. Kansu A, Doganci T, Akman S A, et al. Comparison of two different regimens of combined interferon-alpha 2a and lamivudine therapy in children with chronic hepatitis B infection. Antivir Ther 2006; 11: 255-61.
21. Fung S K, Chae H B, Fontana R J, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-90.
22. Yeon J E, Yoo W, Hong S P, et al. Resistance to adefovir dipivoxil (ADV) in lamivudine-resistant chronic hepatitis B patients treated with ADV. Gut 2006; 55: 1488-95.
23. Lee Y S, Suh D J, Lim Y S, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006; 43: 1385-91.
24. Chang T T, Gish R G, Hadziyannis S J, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 1198-209.
25. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49.
26. Kao J H, Chen P J, Lai M Y, Chen D S. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124: 327-34.
27. Chu C M, Liaw Y F. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: A longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 2005; 43: 411-7.
28. Mahmood S, Niiyama G, Kamei A, et al. Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int 2005; 25: 220-5.
29. Yu M W, Yeh S H, Chen P J, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst 2005; 97: 265-72.
30. Chen B F, Liu C J, Jow G M, Chen P J, Kao J H, Chen D S. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006; 130: 1153-68.
31. Liaw Y-F, Sollano J D. Factors influencing liver disease progression in chronic hepatitis B. Liver Int 2006, in press.
32. Chen C J, Yang H I, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
33. Iloeje U H, Yang H I, Su J, Jen C L, You S L, Chen C J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
34. Liaw Y F. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006; 11: 669-79.
35. Chang T T, Jia J, Omata M, Yoon S K. New therapies for chronic hepatitis B infection. Liver Int 2006, in press.
36. Chu C M, Liaw Y F. Hepatitis B virus-related cirrhosis: Natural history and treatment. Semin Liver Dis 2006; 26: 142-52.
37. Locarnini S. Molecular virology and the development of resistant mutants: Implications for therapy. Semin Liver Dis 2005; 25 (Suppl. 1): 9-19.
38. Locarnini S, Omata M. Molecular virology of HBV and the development of antiviral drug resistance. Liver Int 2006, in press.
39. Chien R N, Liaw Y F, Chen T C, Yeh C T, Sheen I S. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: A randomized, controlled trial. Hepatology 1998; 27: 1383-87.
40. Lai C L, Chien R N, Leung N W, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group. N Engl J Med 1998; 339: 61-8.
41. Dienstag J L, Schiff E R, Wright T L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
42. Lai C L, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
43. Liaw Y F. Results of lamivudine trials in Asia. J Hepatol 2003; 39 (Suppl. 1): S111-5.
44. Liaw Y F. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19 (Suppl. 6): S73-5.
45. Marcellin P. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
46. Hadziyannis S. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
47. Marcellin P, Lau G K, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
48. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-7.
49. Manesis E K, Papatheodoridis G V, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis S J. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol 2003; 98: 2261-7.
50. Lin S M, Tai D I, Chien R N, Sheen I S, Chu C M, Liaw Y F. Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B. J Viral Hepatol 2004; 11: 349-57.
51. Gish R G, Chang T T, de Man R, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022). Hepatology 2005; 42 (Suppl. 1): 267A.
52. Dore G, Guan R, Jafri W, Sarin S. Management of chronic hepatitis B in challenging patient populations. Liver Int 2006, in press.
53. Hui C K, Cheung W W, Au W Y, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 11: 1597-603.
54. Jang J W, Choi J Y, Bae S H, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006; 43: 233-40.
55. Broderick A, Jonas M M. Management of hepatitis B in children. Clin Liver Dis 2004; 8: 387-401.
56. Xu W M, Cui Y T, Wang L, et al. Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis B: A multicentre, randomised, double-blind, placebo-controlled study. Hepatology 2004; 40 (Suppl. 1): 272A.